PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma
Yiqin Wang(Sun Yat-sen University), Ming Jiang(Nanjing Medical University), Liqun Zou(Sichuan University), Wenshuang Ding(Guangzhou First People's Hospital), Hong Zhang(China Geological Survey), Sha Zhao(Nanchang University), Rong Tian(Sichuan University), Wenyan Zhang(Sichuan University), Jie Liu(Sichuan University), Yaotiao Deng(Sichuan University), Weiping Liu(Sichuan University), Li Xie(Xi'an Jiaotong University)
Cited by 14
Related Papers
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma
|Molecular Cancer Research|2007|148
Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: A retrospective study
|International Journal of Hyperthermia|2016|65
Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy
|JAMA Network Open|2022|64
18F-FDG PET and high-resolution MRI co-registration for pre-surgical evaluation of patients with conventional MRI-negative refractory extra-temporal lobe epilepsy
|European Journal of Nuclear Medicine and Molecular Imaging|2018|61